DXR

Conviction 35HealthcareScan · Thu, Jun 25, 2026

DXR$10.50+3.50%

ResistanceSupportVol 14Insider buy

Vol MA14 2.74K

Mar 25Apr 13Apr 30May 18Jun 5Jun 24

DAXOR CORPSURGICAL & MEDICAL INSTRUMENTS & APPARATUSwww.daxor.com ↗

Price10.50

Change+3.50%

Gap+1.80%

Rel volume3.65×

Avg volume2.35K

Avg $ vol23.67K

SMA 209.56

SMA 509.42

SMA 20011.20

Price vs 50+11.45%

Price vs 200-6.21%

MA stackmixed

50/200 cross—

Supertrendup · 4.79

RSI (14)53

MACD hist0.17

MACD crossbull · 4d

Stoch %K / %D95 / 90

ADX (14)7

+DI / −DI44 / 39

RSI divergence—

MACD divergence—

ATR %+18.59%

ADR %5.82%

52w high14.75

52w low0.0000

From 52w high-28.81%

Above 52w low—

New 52w highNo

SqueezeOff

Bollinger width93.61%

%B0.60

Donchian pos94.09%

Donchian high11.16

Donchian low0.0000

AVWAP (52w high)11.08

vs AVWAP high-5.28%

AVWAP (52w low)10.92

vs AVWAP low-3.88%

OBV trendFlat

Chaikin MF (20)-0.02

Today vs 20d3.65×

Avg vol (14d)2.74K

Avg vol (20d)2.35K

Avg $ vol (20d)23.67K

Market cap44.06M

RS 3m (vs SPY)-9.62%

RS 6m (vs SPY)-26.34%

RS line new highNo

Trend template1/8

Technical rank41.7

1 week+5.00%

1 month—

3 months+2.64%

6 months-18.60%

1 year+10.99%

YTD-26.88%

P/E-6.13

P/B1.22

P/S30.46

P/FCF-6.64

EPS-1.70

Div yield2.39%

ROE-19.84%

ROA-8.38%

Debt/Eq—

Current1.66

EV/EBITDA—

Gross margin54.89%

Net margin-496.81%

Rev growth-8.42%

EPS growth-244.63%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value44M

Revenue340.91K

Net income-4.18M

Gross profit191.53K

Free cash flow-6.63M

IndustrySURGICAL & MEDICAL INSTRUMENTS & APPARATUS

ExchangeNasdaq

Shares out5.84M

Employees750

ListedMon, Jul 25, 1983

Free float2.04M

Float %40.5%

Short interest6.16K

Days to cover2.6d

Short volume0.5%

Squeeze score28 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction35 / 100

Pattern quality—

Tech rank41.7 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance11.98

Support0.0000

Days since event—

Candle confirm—

News sentiment—

Financials as of Fri, Sep 30, 2011 · quarterly.

Congress activity

Disclosed STOCK Act trades in DXR

All disclosures →

No recent disclosed trades by Congress in DXR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in DXR · 8 buys

Insider	Side	Shares	Value	Traded	Filed
Cremisi Henry D. Director · Stock Options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
DesRosiers Caleb Director · Stock options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Feuer Edward Director · Stock Options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Goudie Joy S. Director · Stock Options (right to buy) · 2026-06-23	Grant	2.5K	—	2026-06-23	2026-06-25
Feldschuh Jonathan Adam Chief Scientific Officer · Daxor Common Stock · 2026-06-23	Grant	25K	—	2026-06-23	2026-06-25
Feldschuh Michael Richard Chief Executive Officer · Daxor Common Stock · 2026-06-23	Grant	30K	—	2026-06-23	2026-06-25
Michel Robert J Chief Financial Officer · Daxor Common Stock · 2026-06-23	Grant	12K	—	2026-06-23	2026-06-25
Feldschuh Michael Richard Chief Executive Officer · Daxor Common Stock · 2026-04-08	Buy	1K	$9K	2026-04-08	2026-04-10

SEC filings

EDGAR filings in DXR · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.